BioChem Troxatyl Could Be 2002 Launch For Shire Post-Merger
Executive Summary
The leukemia therapy Troxatyl will likely be the first BioChem Pharma product Shire markets following the $4 bil. merger of the two companies.
You may also be interested in...
Shire Adderall DTC Superiority Claims Require Stronger Clinical Data - FDA
Data presented in Shire's Adderall (amphetamine) promotional materials demonstrate comparability between Adderall and Novartis' Ritalin (methylphenidate) at lower doses, rather than superiority, as the promotional materials claim, an FDA ad division letter to Shire maintains.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials